HPRA Drug Safety Newsletter Edition 98

Download: hpra-drug-safety-issue-number-98.pdf 436 KB

The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

- Adverse reaction reporting during the COVID-19 pandemic – reminder

- Picato (ingenol mebutate) – EMA review concludes negative benefit risk balance due to risk of skin malignancy

- Levetiracetam – risk of abnormal and aggressive behaviours

- Cyproterone acetate – restrictions in use due to risk of meningioma

- Carbimazole and propylthiouracil – use in pregnancy and in women of childbearing potential

- Carbimazole – risk of acute pancreatitis

- Testosterone-containing medicinal products: caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE)

« Back